Ciprofloxacin dry powder for inhalation in patients with moderate-to-severe COPD

Trial Profile

Ciprofloxacin dry powder for inhalation in patients with moderate-to-severe COPD

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Oct 2011

At a glance

  • Drugs Ciprofloxacin (Primary)
  • Indications Bacterial infections; Chronic obstructive pulmonary disease
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Bayer HealthCare Pharmaceuticals
  • Most Recent Events

    • 12 Oct 2011 New trial record
    • 28 Sep 2011 Results presented at the 21st Annual Congress of the European Respiratory Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top